Success Metrics

Active Trials

2(67%)

Phase Distribution

Ph not_applicable

67%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 1Safety & dosage

1(33.3%)

N/ANon-phased studies

2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Detailed Status

Active, not recruiting2

Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 1

Trials by Phase

Phase 11 (33.3%)

N/A2 (66.7%)

Trials by Status

enrolling_by_invitation133%

active_not_recruiting267%

Recent Activity

2 active trials

Showing 3 of 3

active_not_recruitingnot_applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

NCT05911178

active_not_recruitingphase_1

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368

enrolling_by_invitationnot_applicable

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

NCT06731842

Clinical Trials (3)

Showing 3 of 3 trials

NCT05911178Not Applicable

Impact of Microglial Activation on Synaptic Density in Alzheimer's Disease

Active Not Recruiting

NCT05464368Phase 1

R21 Roche: 3-Way Tau Tracers in AD

Active Not Recruiting

NCT06731842Not Applicable

Molecular PET Imaging and Plasma Biomarkers in Alzheimer´s Disease and Other Neurodegenerative Diseases

Enrolling By Invitation

All 3 trials loaded

Drug Details

Intervention Type: RADIATION
Total Trials: 3